70
Views
0
CrossRef citations to date
0
Altmetric
Comments

Pairing obinutuzumab with venetoclax in relapsed CLL

&
Pages 543-545 | Received 20 Feb 2024, Accepted 21 Feb 2024, Published online: 18 Mar 2024
 

Acknowledgements

KAR is a Scholar in Clinical Research of the Leukemia & Lymphoma Society.

Disclosure statement

KAR receives research funding from Genentech, AbbVie, and Novartis, consults for Genentech, AbbVie, Pharmacyclics, Janssen, AstraZeneca, BeiGene, LOXO@Lilly, and Alpine Immune Sciences. P.A.T. has served as a paid consultant for AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, Beigene, Genentech, Janssen, Lilly, and Merck and received honoraria from AbbVie, Adaptive Biotechnologies, AstraZeneca, Janssen and Merck.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.